A realistic photo of an adolescent holding doxycycline medication in a clinic setting, symbolizing a study on its potential to reduce schizophrenia risk.
Hoton da AI ya samar

Common acne drug may protect against schizophrenia

Hoton da AI ya samar
An Binciki Gaskiya

A large Finnish registry study suggests that doxycycline, an antibiotic widely used for acne, may lower the risk of schizophrenia among adolescents receiving mental health care, with teens prescribed the drug showing roughly a 30–35% reduced risk compared with peers given other antibiotics.

Scientists from the University of Edinburgh, the University of Oulu, and University College Dublin examined national Finnish health records for more than 56,000 adolescents who had been prescribed antibiotics while attending adolescent psychiatric services. The study, published in the American Journal of Psychiatry, found that those treated with doxycycline were about one-third less likely to develop schizophrenia later in life than those given other antibiotics. (ed.ac.uk)

The analysis used an emulated target trial design on individuals born in 1987–1997, following them from their first dispensed antibiotic prescription up to age 30. Of 56,395 eligible adolescents, 16,189 (about 29%) had used doxycycline. At 10 years, schizophrenia risk was 2.1% among those who received non‑doxycycline antibiotics versus 1.4–1.5% among those exposed to doxycycline, corresponding to relative risk reductions of roughly 30–35%. (pubmed.ncbi.nlm.nih.gov)

Researchers say a plausible explanation is doxycycline’s anti‑inflammatory action and potential effects on synaptic pruning, the brain’s process of refining neural connections during development; excessive pruning has been linked to schizophrenia. The team also reported that the findings were unlikely to be explained by acne treatment versus infection treatment or by other hidden group differences. (ed.ac.uk)

“As many as half of the people who develop schizophrenia had previously attended child and adolescent mental health services for other mental health problems. At present, though, we don’t have any interventions that are known to reduce the risk of going on to develop schizophrenia in these young people. That makes these findings exciting,” said Professor Ian Kelleher, the study’s lead author and Professor of Child and Adolescent Psychiatry at the University of Edinburgh. (ed.ac.uk)

Kelleher cautioned that the work is observational, not a randomized controlled trial, so it cannot establish causality—a point echoed by independent experts, who note that additional research will be needed to confirm whether doxycycline itself reduces risk. (ed.ac.uk)

The international collaboration included partners from St John of God Hospitaller Services Group, and the study received funding from the Health Research Board. (ed.ac.uk)

Labaran da ke da alaƙa

Photorealistic image of zoliflodacin antibiotic pill next to The Lancet journal reporting successful phase 3 trial results for gonorrhea treatment.
Hoton da AI ya samar

Lancet reports phase 3 results for single-dose oral zoliflodacin in uncomplicated gonorrhea

An Ruwaito ta hanyar AI Hoton da AI ya samar An Binciki Gaskiya

Results from a global phase 3 trial of zoliflodacin, an investigational single-dose oral antibiotic, were published in The Lancet in December 2025, showing the drug was non-inferior to a ceftriaxone-based standard regimen for curing uncomplicated urogenital gonorrhea in a study of 930 participants across five countries.

Researchers report that small doses of the antibiotic cephaloridine can prompt certain gut bacteria to increase production of colanic acid, a microbial polysaccharide previously tied to longer lifespan in laboratory animals. In experiments, treated roundworms lived longer and mice showed shifts in cholesterol or insulin measures associated with aging, with the team arguing the approach works by acting in the gut rather than throughout the body.

An Ruwaito ta hanyar AI

A new oral antibiotic called zoliflodacin has shown effectiveness in treating gonorrhoea, clearing 91 percent of infections in a clinical trial. The drug offers a potential alternative to the increasingly resistant standard treatment of ceftriaxone. With resistance to existing antibiotics rising globally, this development could help delay the emergence of untreatable strains.

Researchers at the University of Cambridge report that 168 widely used industrial and agricultural chemicals slowed or stopped the growth of bacteria commonly found in a healthy human gut in laboratory experiments, raising questions about whether routine chemical exposure could affect the microbiome and, in some cases, antibiotic resistance.

An Ruwaito ta hanyar AI

As antibiotics increasingly fail, researchers at AIIMS Delhi are leading the battle against superbugs through early diagnosis, biomarker research, and rational antibiotic use. A recent case of a 50-year-old man with resistant bacterial meningitis underscores the urgency. The institute is running multiple projects to slow down antimicrobial resistance.

A large-scale genetic analysis of about 1.09 million people suggests that lifelong, genetically lower cholesterol—specifically non‑HDL cholesterol—is associated with substantially reduced dementia risk. Using Mendelian randomization to emulate the effects of cholesterol‑lowering drug targets such as those for statins (HMGCR) and ezetimibe (NPC1L1), the study found up to an approximately 80% lower risk per 1 mmol/L reduction for some targets. ([research-information.bris.ac.uk](https://research-information.bris.ac.uk/en/publications/cholesterollowering-drug-targets-reduce-risk-of-dementia-mendelia?utm_source=openai))

An Ruwaito ta hanyar AI

Researchers have found that psilocybin, the hallucinogenic compound in magic mushrooms, likely evolved as a defense mechanism against insects that feed on fungi. Experiments with fruit fly larvae showed reduced survival and impaired development when exposed to the substance. This discovery sheds light on the evolutionary purpose of psychedelics in nature.

 

 

 

Wannan shafin yana amfani da cookies

Muna amfani da cookies don nazari don inganta shafin mu. Karanta manufar sirri mu don ƙarin bayani.
Ƙi